BCMA CAR-T Cell Therapy for High-risk Multiple Myeloma Patients

Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.

This study is testing a new CAR-T cell therapy to see if it can help high-risk multiple myeloma patients who still have signs of the disease after their first stem cell transplant.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China (Academic / other)
• Drugs / interventions: CAR-T, CART
• Locations: 1 site (Tianjin, Tianjin)
• Trial ID: NCT05846737 on ClinicalTrials.gov

What this trial studies

This Phase 2 study evaluates the safety and efficacy of BCMA CAR-T Cell Therapy in patients with high-risk newly diagnosed multiple myeloma (NDMM) who have detectable minimal residual disease (MRD) after first-line autologous stem cell transplantation (ASCT). The study will enroll 40 subjects and is designed as an open-label, single-center trial. Participants must have undergone ASCT and have measurable MRD using specific testing methods within a defined timeframe post-transplant.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with high-risk NDMM and detectable MRD after ASCT.

Not a fit: Patients who do not have detectable MRD after ASCT or those with lower-risk multiple myeloma may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could significantly improve outcomes for high-risk multiple myeloma patients who currently have limited treatment options.

How similar studies have performed: While CAR-T therapies have shown promise in hematological malignancies, this specific application in high-risk NDMM with MRD is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Age ≥ 18 years.
2. Participants with documented NDMM according to IMWG diagnostic criteria.
3. High-risk MM, as determined by R2-ISS（J Clin Oncol, 2022,40(29):3406-3418.）, Stage III or Stage IV.
4. Has received 3 to 6 cycles of induction therapy, followed by conditioning regimen and ASCT.
5. Screening must be completed within 100 days of ASCT.
6. For subjects receiving consolidation therapy after ASCT, screening must be completed within 60 days after consolidation therapy, and within 6 months after ASCT.
7. Detectable MRD using EuroFlow or NGS, at 100 days after ASCT (minimum sensitivity of 10-5).
8. All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL\<1.5 x upper limit of normal (ULN) (\<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT \<3 x ULN.; c. Creatinine clearance \> 60mL/min (calculated using the Cockroft-Gault formula).
9. Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 85 g/L PLT ≥ 75 x 109/L (if BMPC \< 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
10. Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
11. The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.

Exclusion Criteria:

1. Primary plasma cell leukemia.
2. Documented active amyloidosis.
3. Multiple myeloma with central nervous system (CNS) invasion.
4. Has received maintenance therapy.
5. Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
6. Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
7. Known intolerance, hypersensitivity, or contraindication to BCMA-CART cellular products.
8. Seropositive for human immunodeficiency virus (HIV).
9. Hepatitis B infection.
10. Hepatitis C infection.
11. Life expectancy of \<3 months.
12. Women who are pregnant or breastfeeding.
13. Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
14. Received live attenuated vaccine within 4 weeks prior to study treatment.
15. According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
16. Necessary medication or supportive therapy is contraindicated with study treatment.
17. Any diseases or complications that may interfere with the study.
18. Patients are not willing to or cannot comply with study scheme.

Where this trial is running

Tianjin, Tianjin

• Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences — Tianjin, Tianjin, China (Recruiting)

Study contacts

• Study coordinator: Gang An, PhD&MD

Conditions Multiple Myeloma